COMMUNIQUÉS West-GlobeNewswire

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
05/03/2026
Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177 Lu-edotreotide arm vs. 14.7 months on everolimus arm Objective response rate (ORR) was higher across the [...]
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
05/03/2026
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports [...]
Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call
05/03/2026
SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will [...]
Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026
05/03/2026
Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085 ) evaluating its lead candidate PRI- [...]
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
05/03/2026
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents [...]
Repligen Corporation to Present at Upcoming March Conferences
05/03/2026
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three [...]
Independent Peterson Health Technology Institute evaluation validates impact of Cylinder Health’s digestive care model
05/03/2026
Peer-reviewed studies show reductions in medical costs, symptom burden, and workplace absenteeism CHICAGO, March 05, 2026 (GLOBE NEWSWIRE) -- The Peterson Health Technology Institute (PHTI) has released an independent [...]
CervoMed to Participate in Upcoming Investor Conferences
05/03/2026
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will [...]
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
05/03/2026
CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Swarm Oncology appoints Bernhard Ehmer as Chairman
05/03/2026
Company announces manufacturing readiness and financing extension ahead of first-in-human clinical study London, United Kingdom, March 5, 2026, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm” or “the Company”), a [...]
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
05/03/2026
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5 , 202 6 . The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting [...]
Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
05/03/2026
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated [...]
Oculis Publishes 2025 Consolidated Financial Statements
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now [...]
Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante
05/03/2026
Le Conseil d’administration de Sanofi propose la nomination de C hristel Heydemann en qualité d’administrat rice indépendant e Paris , le 5 mars 202 6 . Le Conseil d’administration de Sanofi a décidé de proposer, dans [...]
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
05/03/2026
BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious [...]
Phonak Infinio Ultra Sphere and Virto R Infinio win 2026 iF DESIGN AWARD
05/03/2026
Both Phonak hearing aids recognized for seamlessly integrating breakthrough technology with intuitive usability and refined industrial design STÄFA, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Phonak , a global [...]
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
05/03/2026
Ghent, Belgium, March 05, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION 5 March 2026, 7:00 am CET Ghent, Belgium, 5 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " [...]

Pages